A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma

Summary

To observe the efficacy and safety of a new generation of BTK inhibitor Orelabrutinib combined with PD-1 and fotemustine in the treatment of patients with primary central nervous system lymphoma (PCNSL).

Timeline

Start

2021-03-29

Primary completion

2023-09-15

Completion

2024-09-15

Publications

• Zhao W, Li L, Fu X, Chang Y, Sun Z, Zhu L, Li X, Wang X, Yan J, Jia S, Ma S, Fan M, Qian S, Zhang Y, Yang Q, Qiao H, Chen Q, Zhang M, Zhang X. A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma. Cancer. 2026 Jan 1;132(1):e70247. doi: 10.1002/cncr.70247.

Drugs

Indications